Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Goodwill & Intangibles (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Goodwill & Intangibles for 5 consecutive years, with $13.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Goodwill & Intangibles fell 2.45% to $13.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.2 million, a 2.45% decrease, with the full-year FY2025 number at $13.4 million, changed N/A from a year prior.
  • Goodwill & Intangibles was $13.2 million for Q4 2025 at Neuphoria Therapeutics, down from $13.3 million in the prior quarter.
  • In the past five years, Goodwill & Intangibles ranged from a high of $16.3 million in Q2 2022 to a low of $13.2 million in Q4 2025.
  • A 4-year average of $14.0 million and a median of $13.5 million in 2024 define the central range for Goodwill & Intangibles.
  • Peak YoY movement for Goodwill & Intangibles: dropped 8.41% in 2023, then dropped 2.45% in 2025.
  • Neuphoria Therapeutics' Goodwill & Intangibles stood at $16.3 million in 2022, then fell by 8.41% to $14.9 million in 2023, then dropped by 9.08% to $13.5 million in 2024, then decreased by 2.45% to $13.2 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Goodwill & Intangibles are $13.2 million (Q4 2025), $13.3 million (Q3 2025), and $13.4 million (Q2 2025).